648 related articles for article (PubMed ID: 22623692)
1. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL.
Hylton NM; Blume JD; Bernreuter WK; Pisano ED; Rosen MA; Morris EA; Weatherall PT; Lehman CD; Newstead GM; Polin S; Marques HS; Esserman LJ; Schnall MD;
Radiology; 2012 Jun; 263(3):663-72. PubMed ID: 22623692
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL.
Hylton NM; Gatsonis CA; Rosen MA; Lehman CD; Newitt DC; Partridge SC; Bernreuter WK; Pisano ED; Morris EA; Weatherall PT; Polin SM; Newstead GM; Marques HS; Esserman LJ; Schnall MD;
Radiology; 2016 Apr; 279(1):44-55. PubMed ID: 26624971
[TBL] [Abstract][Full Text] [Related]
3. Investigating the prediction value of multiparametric magnetic resonance imaging at 3 T in response to neoadjuvant chemotherapy in breast cancer.
Minarikova L; Bogner W; Pinker K; Valkovič L; Zaric O; Bago-Horvath Z; Bartsch R; Helbich TH; Trattnig S; Gruber S
Eur Radiol; 2017 May; 27(5):1901-1911. PubMed ID: 27651141
[TBL] [Abstract][Full Text] [Related]
4. MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial.
Scheel JR; Kim E; Partridge SC; Lehman CD; Rosen MA; Bernreuter WK; Pisano ED; Marques HS; Morris EA; Weatherall PT; Polin SM; Newstead GM; Esserman LJ; Schnall MD; Hylton NM;
AJR Am J Roentgenol; 2018 Jun; 210(6):1376-1385. PubMed ID: 29708782
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer: early prediction of response to neoadjuvant chemotherapy using parametric response maps for MR imaging.
Cho N; Im SA; Park IA; Lee KH; Li M; Han W; Noh DY; Moon WK
Radiology; 2014 Aug; 272(2):385-96. PubMed ID: 24738612
[TBL] [Abstract][Full Text] [Related]
6. Predicting pathologic response to neoadjuvant chemotherapy in breast cancer by using MR imaging and quantitative 1H MR spectroscopy.
Baek HM; Chen JH; Nie K; Yu HJ; Bahri S; Mehta RS; Nalcioglu O; Su MY
Radiology; 2009 Jun; 251(3):653-62. PubMed ID: 19276320
[TBL] [Abstract][Full Text] [Related]
7. Changes in primary breast cancer heterogeneity may augment midtreatment MR imaging assessment of response to neoadjuvant chemotherapy.
Parikh J; Selmi M; Charles-Edwards G; Glendenning J; Ganeshan B; Verma H; Mansi J; Harries M; Tutt A; Goh V
Radiology; 2014 Jul; 272(1):100-12. PubMed ID: 24654970
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging--prospective assessment.
Tateishi U; Miyake M; Nagaoka T; Terauchi T; Kubota K; Kinoshita T; Daisaki H; Macapinlac HA
Radiology; 2012 Apr; 263(1):53-63. PubMed ID: 22438441
[TBL] [Abstract][Full Text] [Related]
9. Primary human breast adenocarcinoma: imaging and histologic correlates of intrinsic susceptibility-weighted MR imaging before and during chemotherapy.
Li SP; Taylor NJ; Makris A; Ah-See ML; Beresford MJ; Stirling JJ; d'Arcy JA; Collins DJ; Padhani AR
Radiology; 2010 Dec; 257(3):643-52. PubMed ID: 20858850
[TBL] [Abstract][Full Text] [Related]
10. Impact of Machine Learning With Multiparametric Magnetic Resonance Imaging of the Breast for Early Prediction of Response to Neoadjuvant Chemotherapy and Survival Outcomes in Breast Cancer Patients.
Tahmassebi A; Wengert GJ; Helbich TH; Bago-Horvath Z; Alaei S; Bartsch R; Dubsky P; Baltzer P; Clauser P; Kapetas P; Morris EA; Meyer-Baese A; Pinker K
Invest Radiol; 2019 Feb; 54(2):110-117. PubMed ID: 30358693
[TBL] [Abstract][Full Text] [Related]
11. Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
Campbell JI; Yau C; Krass P; Moore D; Carey LA; Au A; Chhieng D; Giri D; Livasy C; Mies C; Rabban J; Sarode VR; Singh B; Esserman L; Chen YY
Breast Cancer Res Treat; 2017 Aug; 165(1):181-191. PubMed ID: 28577078
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer: evaluation of response to neoadjuvant chemotherapy with 3.0-T MR imaging.
Chen JH; Bahri S; Mehta RS; Kuzucan A; Yu HJ; Carpenter PM; Feig SA; Lin M; Hsiang DJ; Lane KT; Butler JA; Nalcioglu O; Su MY
Radiology; 2011 Dec; 261(3):735-43. PubMed ID: 21878615
[TBL] [Abstract][Full Text] [Related]
13. Breast Cancer: Influence of Taxanes on Response Assessment with Dynamic Contrast-enhanced MR Imaging.
Schrading S; Kuhl CK
Radiology; 2015 Dec; 277(3):687-96. PubMed ID: 26176656
[TBL] [Abstract][Full Text] [Related]
14. Diffusion-weighted magnetic resonance imaging for pretreatment prediction and monitoring of treatment response of patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy.
Nilsen L; Fangberget A; Geier O; Olsen DR; Seierstad T
Acta Oncol; 2010 Apr; 49(3):354-60. PubMed ID: 20397769
[TBL] [Abstract][Full Text] [Related]
15. MR spectroscopy of breast cancer for assessing early treatment response: Results from the ACRIN 6657 MRS trial.
Bolan PJ; Kim E; Herman BA; Newstead GM; Rosen MA; Schnall MD; Pisano ED; Weatherall PT; Morris EA; Lehman CD; Garwood M; Nelson MT; Yee D; Polin SM; Esserman LJ; Gatsonis CA; Metzger GJ; Newitt DC; Partridge SC; Hylton NM;
J Magn Reson Imaging; 2017 Jul; 46(1):290-302. PubMed ID: 27981651
[TBL] [Abstract][Full Text] [Related]
16. Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).
Gampenrieder SP; Peer A; Weismann C; Meissnitzer M; Rinnerthaler G; Webhofer J; Westphal T; Riedmann M; Meissnitzer T; Egger H; Klaassen Federspiel F; Reitsamer R; Hauser-Kronberger C; Stering K; Hergan K; Mlineritsch B; Greil R
Breast Cancer Res; 2019 Jan; 21(1):19. PubMed ID: 30704493
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer: influence of tumour volume estimation method at MRI on prediction of pathological response to neoadjuvant chemotherapy.
Henderson SA; Muhammad Gowdh N; Purdie CA; Jordan LB; Evans A; Brunton T; Thompson AM; Vinnicombe S
Br J Radiol; 2018 Jul; 91(1087):20180123. PubMed ID: 29641224
[TBL] [Abstract][Full Text] [Related]
18. Diffusion-weighted MR imaging: pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer.
Park SH; Moon WK; Cho N; Song IC; Chang JM; Park IA; Han W; Noh DY
Radiology; 2010 Oct; 257(1):56-63. PubMed ID: 20851939
[TBL] [Abstract][Full Text] [Related]
19. Contrast-enhanced MRI after neoadjuvant chemotherapy of breast cancer: lesion-to-background parenchymal signal enhancement ratio for discriminating pathological complete response from minimal residual tumour.
Kim SY; Cho N; Shin SU; Lee HB; Han W; Park IA; Kwon BR; Kim SY; Lee SH; Chang JM; Moon WK
Eur Radiol; 2018 Jul; 28(7):2986-2995. PubMed ID: 29380033
[TBL] [Abstract][Full Text] [Related]
20. MRI Volume Changes of Axillary Lymph Nodes as Predictor of Pathologic Complete Responses to Neoadjuvant Chemotherapy in Breast Cancer.
Cattell RF; Kang JJ; Ren T; Huang PB; Muttreja A; Dacosta S; Li H; Baer L; Clouston S; Palermo R; Fisher P; Bernstein C; Cohen JA; Duong TQ
Clin Breast Cancer; 2020 Feb; 20(1):68-79.e1. PubMed ID: 31327729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]